Higher-BED palliative radiotherapy improved symptoms in rectal cancer
BED >37.5 Gy improved symptomatic control, while 6-month local control remained 46% in frail, elderly, or metastatic rectal cancer.
BED >37.5 Gy improved symptomatic control, while 6-month local control remained 46% in frail, elderly, or metastatic rectal cancer.
Dutch radiation oncologists reported substantial variation in dose, delineation, and follow-up for unresectable locally recurrent rectal cancer.
ESTRO–ASTRO guidance supports selected rectal cancer reirradiation using 30–40 Gy regimens, cumulative dose assessment, inverse planning and daily volumetric imaging.